Lung Cancer

Patient reaches 5-year survival mark after treatment with Advexin

Published in Cancer Weekly, August 13th, 2002

A late-stage lung cancer patient treated with Advexin adenoviral p53 gene drug therapy has survived for 63 months, according to Introgen Therapeutics, Inc. (INGN).

Typically, the midpoint of known survival time is 6 months for end-stage lung cancer patients who, like her, have failed conventional treatments such as surgery or chemotherapy. The patient experienced no significant side effects during treatment.

She received Advexin in 1997 as part of a phase I trial at The University of Texas M. D. Anderson Cancer Center in Houston after being diagnosed with metastatic non-small cell lung cancer. The patient's tumor could not be surgically removed...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-08-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry